Biochemical activities of lactose-derived prebiotics — a review by Nath, A. et al.
0139–3006 © 2017 Akadémiai Kiadó, Budapest
Acta Alimentaria, Vol. 46 (4), pp. 449–456 (2017)
DOI: 10.1556/066.2017.46.4.7
BIOCHEMICAL ACTIVITIES OF LACTOSE-DERIVED PREBIOTICS – 
A REVIEW
A. NATHa*, S. MONDALa, A. CSIGHYa, M.A. MOLNÁRa, K. PÁSZTORNÉ-HUSZÁRb, Z. KOVÁCSa,
A. KORISa and GY. VATAIa*
aDepartment of Food Engineering, Faculty of Food Science, Szent István University, H-1118 Budapest, Ménesi út 
44. Hungary
bDepartment of Refrigeration and Livestock Product Technology, Faculty of Food Science, Szent István 
University, H-1118 Budapest, Ménesi út 43–45. Hungary
(Received: 2 December 2016; accepted: 27 March 2017)
In the dairy industry different types of prebiotics, such galacto-oligosaccharide, lactulose, lactosucrose, tagatose, 
lactitol, lactobiono- and glucono-δ-lactone are synthesized through different chemical and biochemical reactions 
(hydrolysis, transgalactosylation, isomerization, fructosyl-transfer, reduction, and oxidation) as well as microbial 
fermentation processes using raw whey or isolated lactose as feedstock. Lactose-derived prebiotics have several 
functional and nutritional values. The biochemical activities of lactose-based prebiotics are expressed in the presence 
of probiotics (lactic acid bacteria, yeasts, Bacillus spp.). Galacto-oligosaccharide and lactosucrose reduce the risk of 
bowel disorder (diarrhea), infl ammatory bowel disease (ulcerative colitis and crohn's disease), and colon cancer. 
Galacto-oligosaccharide helps colonic absorption of minerals (iron, magnesium and calcium) and prevents 
osteoporosis. Lactulose, galacto-oligosaccharide, and lactitol promote laxative activity. Furthermore, lactulose may 
decrease the risk of hepatic encephalopathy. Prebiotics have low calorifi c value and glycemic index. Galacto-
oligosaccharide and tagatose reduce the risks of hyperglycemia (Type 2 diabetes) and low density lipid (lipoprotein) 
accumulation in blood stream. Moreover, prebiotics improve immunomodulation, which reduces the risk of 
respiratory infection and allergies. This review describes unique biochemical mechanisms of several types of 
lactose-derived prebiotics.
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The major by-product of dairy industry is whey, which comprises 80–90% of the total volume 
of milk entering the process of cheese production (PRAZERES et al., 2012). From a long prior, 
liquid whey or isolated pure lactose have been used for the synthesis of different prebiotics, 
such as galacto-oligosaccharide, lactulose, lactosucrose, tagatose, lactitol, lactobiono- and 
glucono-δ-lactone through different chemical and biochemical reactions, such as hydrolysis, 
transgalactosylation, isomerization, fructosyl-transfer, reduction, and oxidation. In many 
cases microbial fermentation processes have been adopted for lactose-based prebiotics 
synthesis (STYEVKÓ et al., 2013; NATH et al., 2016). They have unique functional and nutritional 
values (Fig. 1). In the present review unique biochemical activities and mechanism of actions 
of several types of lactose-based prebiotics are reported. The articles with keywords lactose, 
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prebiotics, biological activity, prebiotic-probiotic interaction, and human health benefi t have 
been searched judiciously in the Web of Science and information are summarized from the 
articles, published in 1992–2016.
Fig. 1. Different functional and nutritional values of lactose-derived prebiotics (fi gure compiled by the authors 
based on NAGPAL and co-workers, 2012 and NATH and co-workers, 2016).
1. Functional and biological activities of lactose-based prebiotics
The criteria of a prebiotic are determined by its resistance to upper tract of gut enzymes, no 
absorption through the gastrointestinal tract, stable during food processing, broken down by 
intestinal microbiota (probiotics), and the selective stimulation of growth and/or activity of 
probiotics (WANG, 2009). Probiotics Lactobacillus spp. reside mainly in the small intestine, 
while Bifi dobacterium spp. are generally present in the large intestine. They are able to 
survive in gastric acidity, antibiotics, lysozyme, and other hostile conditions in the 
gastrointestinal tract. The biological activities of lactose-based prebiotics are expressed in the 
presence of probiotics. The interactions between prebiotics and probiotics can reduce several 
health problems as well as promote sustainable health (NAGPAL et al., 2012). Probiotics have 
the potential to break down prebiotics in the gastrointestinal tract due to their unique gene 
construction. The rate of fermentation of the individual prebiotic depends on the carbohydrate 
monomer, glycosidic linkage, degree of polymerisation, interaction with gut bacteria, 
fermentation mechanism, and saccharolytic capacity of the probiotic (GOH & KLAENHAMMER, 
2015).
1.1. Inhibition of bowel disorder and infl ammatory bowel disease
Prebiotics galacto-oligosaccharide and lactosucrose can prevent the colonization of the 
gastrointestinal tract by pathogens and reduce the risks of several bowel disorders (antibiotic 
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associated diarrhea, traveler’s diarrhea, acute watery diarrhea, Clostridium diffi cile associated 
relapsing diarrhea), and infl ammatory bowel diseases (Crohn’s disease and ulcerative colitis). 
There are different biochemical actions regarding the inhibition mechanisms of pathogens by 
probiotics in the presence of prebiotics (SZEKÉR et al., 2007; AURELI et al., 2011). The 
mechanisms include (a) competitive exclusion of pathogens (antiadhesion effect) by 
probiotics, (b) synthesis of bacteriocins by probiotics, (c) biotransformation of the prebiotic 
into lactic acid and short chain fatty acids (acetic acid, propanoic acid, and butyric acid), (d) 
competition for nutrients among pathogens and probiotics, (e) development of immuno-
modulation, and (f) synthesis of antigens (this mechanism proceeds via production of 
cytokines, such as Interleukin-10, which inhibit the T-helper 1, T-helper 2, T-helper 7 and 
T-helper 17, and transforming growth factor-β, which produces immunoglobulin A) 
(OELSCHLAEGER, 2010). The mechanisms are represented in Figure 2.
Fig. 2. Mechanisms of inhibition of pathogens by probiotics (fi gure compiled by the authors based on KHALIGHI 
and co-workers, 2016)
1.2. Reduction of hepatic encephalopathy
Typically, prebiotic lactulose is considered for treatment of hepatic encephalopathy, caused 
by accumulation of the toxic bacterial metabolites (ammonia) in blood stream due to liver 
damage. There are three suggested mechanisms through which prebiotic lactulose reduces 
the risk of hepatic encephalopathy; (1) a decrease in total ammonia in the portal blood by (a) 
decreasing bacterial urease activity, (b) decreasing ammonia absorption by decreasing pH, 
(c) improving the nutritional status of gut epithelium, (d) decreasing intestinal permeability; 
(2) a decrease in oxidative stress and infl ammation in the hepatocytes, leading to an increased 
hepatic clearance of toxins and ammonia; and (3) a decrease in the uptake of other toxins 
(SOLGA, 2003). Lactulose is broken down into short chain fatty acids as well as hydrogen and 
carbon dioxide by probiotic bacteria (Bifi dobacterium spp. and Lactobacillus spp.) in the 
lower gut. Substantial hydrogen and carbon dioxide in the lower gut cause a rapid intestinal 
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hurry and thus massive amounts of colonic microorganisms, such as urease-positive bacteria 
and deaminating bacteria are removed. As a result, intestinal uptake of the toxic bacterial 
metabolites, e.g. ammonia, is reduced (BONGAERTS et al., 2005).
1.3. Reduction of risk of colon cancer
It has long been reported that certain bacterial metabolites in the large intestine are associated 
with negative effects on the host cell and could lead to initiation and/or proliferation of colon 
carcinogenesis. In particular, bacterial synthesized enzymes, such as β-glucuronidase, 
β-glucosidase, azoreductase, and nitroreductase are associated with the appearance of colon 
carcinogens (KUMAR et al., 2015). Lactose-derived pebiotics are broken down by gut 
probiotics and converted into different short chain fatty acids, which reduce the pH of the 
colon. At lower pH, pathogenic bacteria cannot survive in the intestine. Also, due to 
antiadhesion effect of lactose-based prebiotics, competition for nutrients, and negative 
infl uence of probiotic synthesized bacteriocins, the undesirable colonic microorganism are 
hindered. As a result, production and activities of genotoxic enzymes are impeded, and risk 
of appearance of colon cancer is reduced (BUGAUT & BENTÉJAC, 1993). Prebiotic-derived 
butyric acid is revealed as a potential inhibitor of growth and inducer of phenotype 
differentiation and apoptosis. It also reduces risk factors of colon cancer and tumor 
development (WOLLOWSKI et al., 2001). Butyrate and acetate are able to alter the gene-
expression in tumor cells and reduce the induction of DNA damage (HAGUE et al., 1995; 
MARCHETTI et al., 1997). In colon cells, glutathione transferase Pi is the most abundant, and it 
is an important enzyme involved in the detoxifi cation of both electrophilic products and 
compounds associated with oxidative stress. The synthesis of enzyme glutathione transferase 
Pi in colon cells is increased by butyrate (CSORDAS, 1995; TREPTOW-VAN LISHAUT et al., 1999). 
It has been reported that butyrate is the major source of energy for colonocytes, which helps 
to maintain a healthy epithelium and to an extent prevents cancer (TOPPING & CLIFTON, 2001).
1.4. Improvement of mineral absorption
It was reported that prebiotic galacto-oligosaccharide plays a crucial role in the colonic 
absorption of minerals; particularly calcium, magnesium, and iron, which are responsible for 
developing bone structure, preventing osteoporosis and cell development (SCHOLZ-AHRENS et 
al., 2007). Probiotics ferment galacto-oligosaccharide in the intestine and produce short 
chain fatty acids, so guts become acidic. Inorganic salts, such as iron, magnesium, and 
calcium salts are insoluble at a neutral pH. The acidifi cation of the intestine makes the 
calcium (CHONAN et al., 1995, 1996; VAN DEN HEUVEL et al., 1998), magnesium (CHONAN et al., 
1996), and iron (VAN DEN HEUVEL et al., 1998) salts soluble, which leads to their increased 
absorption in the intestine.
1.5. Controlling blood lipids
Lactose-based prebiotics, such as galacto-oligosaccharide (VULEVIC et al., 2013) and tagatose 
(POLICE et al., 2009) play a crucial role in lipid regulation, although the exact mechanism is 
still unclear. Few possible mechanisms are (1) the deconjugation of bile acids through bile 
salt hydrolase catalysis, (2) the capture and assimilation of cholesterol for stabilization of 
their cell membranes, (3) binding cholesterol to the cell membrane of probiotics in the 
gastrointestinal tract, (4) conversion of cholesterol into coprostanol, and (5) inhibition of 
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hepatic cholesterol synthesis by short chain fatty acids produced by probiotic bacteria and/or 
redistribution of cholesterol from plasma to the liver (HOMAYOUNI et al., 2012).
1.6. Controlling blood glucose level
It has been reported that lactose-based prebiotics, such as galacto-oligosaccharide (SANGWAN 
et al., 2015) and tagatose (ENSOR et al., 2015), reduce the long-standing elevated level of 
blood glucose (hyperglycemia). Several possible mechanisms have been published. In the 
intestine, lactose-derived prebiotics are transformed to short chain fatty acids by probiotics. 
It has been reported that short chain fatty acids may affect plasma glucose levels by increasing 
the gut hormones GLP-1 and PYY, via activation of the receptors Ffar3 and Ffar2 (KELLOW 
et al., 2014; KASUBUCHI et al., 2015). Lactose derived prebiotics promote the growth of 
probiotics, those offer anti-diabetic effects against insulin resistance and infl ammation by 
increasing liver natural killer T cells, modulating tumor necrosis factor-α expression and 
reducing nuclear factor-κB binding activity (MA et al., 2008). Furthermore, probiotics may 
improve glucose metabolism by delaying or inhibiting the intestinal absorption of glucose, 
increasing the bioavailability of gliclazide (AL-SALAMI et al., 2008) and altering the activity 
of autonomic nervous system (YAMANO et al., 2006).
1.7. Improvement of immune system
Lactose-based prebiotics play a crucial positive role in the development of immune system, 
both before vaccination and as adjuvant in vaccines. Prebiotics in the presence of probotics 
regulate both systemic and mucosal immunities. Interactions of prebiotics and probiotics can 
modulate the activities of different cells of the immune system, such as natural killer cells, 
dendritic cells, macrophages, granulocytes, epithelial cells, as well as adaptive system 
T-helper 1, T-helper 17, regulatory T cells, T lymphocytes, and B lymphocytes (KLAENHAMMER 
et al., 2012; HARDY et al., 2013). It is well documented that prebiotic galacto-oligosaccharide 
is broken down by probiotic bifi dobacteria, lactobacilli and short chain fatty acids are 
synthesized. Butyric acid suppresses the lymphocyte proliferation, inhibits cytokine 
production from T-helper 1-lymphocytes, and upregulates interleukin-10 production. It also 
suppresses the expression of the transcription factor such as nuclear factor-κB and upregulates 
Toll-like receptors expression (HOYLES & VULEVIC, 2008; AMIT-ROMACH et al., 2010). It has 
been reported that the symbiotic effect of probiotic and galacto-oligosaccharide reduces the 
risk of immunoglobulin E-associated allergies, such as eczema (dermatitis), allergic rhinitis, 
or asthma. Beside that, lactose-derived prebiotics reduce the risk of respiratory infections 
(otitis media, sinusitis, bronchitis, and pneumonia) (BRUZZESE et al., 2009).
1.8. Anti-constipation
For a long time, prebiotic lactulose has been popularly used for the treatment of constipation 
(THERESA & PETTIT-YOUNG, 1992). Lactulose and other disaccharides (example: lactitol) are 
broken down by probiotics, and different types of short chain fatty acids are synthesized, the 
gut becomes more acidic, leading to a reduction of ammonia absorption in mucosa. The 
presence of ammonia in the gut causes water to be drawn into the lower intestine, which 
increases the amount of water in stool, softening and making it pass more easily, reducing the 
transit time of constipated subjects (SCHUMANN, 2002).
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1.9. Low caloric value
Lactose-based prebiotics have low calorifi c value and are benefi cial to everybody regardless 
of age or gender. Lactose-derived prebiotics are resistant to salivary degradation as well as 
the digestion of pancreatic enzymes and gastric juices. Therefore, they offer lower glycemic 
index values and a calorifi c value 50% lower than sucrose. CUMMINGS and co-workers (1997) 
reported that calorifi c value of galacto-oligosaccharide is 1–2 kcal g–1. According to the 
Japanese standard method, the calorifi c value of galacto-oligosaccharide was 1.73 kcal g–1 
(SCHAAFSMA, 2008).
2. Conclusions
Different types of lactose-derived prebiotics are synthesized through different chemical and 
biochemical reactions and microbial fermentation processes. In the present review, several 
biochemical actions of different types of lactose-derived prebiotics are described. However, 
while more promising potential health effects of prebiotics are being summarized in the 
current article, there are many biochemical outcomes of probiotic and prebiotic interactions 
that are still unclear. Therefore, more investigations in this area are prerequisite. It is hoped 
that this review will receive the attention of medical practitioners, food and nutrition research 
communities, and will open a new area in the fi eld of waste valorization.
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